Table 1.

Characteristics of the included studies.

		Diagnostic	Treatment		Interventions		Outcome
Authors	County	patients (T/C)	criteria	Duration	T	C	measurements
Zheng et al (2018)[13]	China	100/100	Rome III	4 wk	EA	Sham-EA	1. Effective rate
							2. LDQ scores
							3. NDI
Qiang et al (2018)[14]	China	32/32	Rome III	30 d	EA	Mosapride	1. Effective rate
							2. LDQ scores
							3. FDDQL scores
							4. Ghrelin, CGRP and GLP-1 level
Zhang et al (2015)[15]	China	159/160	Rome III	4 wk	EA	Mosapride	1. Effective rate
							2. Symptom scores
							3. SF-36 scores
							4. Plasma motilin level
							5. EGG
							6. Gastric empty
Xu et al (2015)[16]	China	8/8	Rome III	30 min	EA	Sham-EA	1. EGG
							2. HRV
							3. Symptom scores
Guo et al (2011)[17]	China	80/80	Rome III	6 wk	EA	Mosapride,	1. Symptom scores Omeprazole,
							2. Effective rate Amitriptyline
							3. NDSI scores
							4. SF-36 scores
							5. EGG
							6. Plasma motilin
							7. Gastric empty
Peng et al (2008)[18]	China	20/20	Rome III	2 wk	EA	Domperidone	1. Symptom scores
							2. SAS
							3. SDS
							4. HRV
							5. EGG
							6. Neuropeptide level
Liu et al(ACT) (2008)[12]	China	27/27	Rome II	30 min	EA	Sham-EA	1. HRV
							2. EGG
Liu et al(CCT) (2008)[12]	China	27/27	Rome II	2 wk	EA	Sham-EA	1. Symptom scores
							2. HRV
							3. EGG
							4. Neuropeptide level
							5. Plasma motilin level